Revance Therapeutics reported $74.73M in Current Liabilities for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
ALKERMES ALKS:US USD 469.56M 31.04M
Bristol Myers Squibb BMY:US USD 18.93B 1.98B
Cara Therapeutics CARA:US USD 28.19M 7.02M
Coherus Biosciences CHRS:US USD 171.32M 30.56M
Eli Lilly And LLY:US USD 15.65B 32.2M
Endo International Ordinary Shares ENDP:US USD 543.05M 638.62M
Horizon Pharma HZNP:US USD 860.61M 69.55M
JAZZ PHA JAZZ:US USD 812.95M 107.51M
Neurocrine Biosciences NBIX:US USD 485.1M 199.4M
Pacira Pharmaceuticals PCRX:US USD 131.53M 1.65M
Procter & Gamble PG:US USD 38.75B 2.13B
Revance Therapeutics RVNC:US USD 74.73M 2.49M
Supernus Pharmaceuticals SUPN:US USD 725.99M 9.55M
Teva Pharmaceutical Industries TEVA:US USD 11.53B 538M